Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 3Recurrence 2Myeloid Malignancies 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Blast Crisis 1

Interventions

Cyclophosphamide 9fludarabine 7Dexamethasone 7pomalidomide 6Rituximab 6pembrolizumab 5selinexor 4obinutuzumab 4glofitamab 4Lenalidomide 4daratumumab 3belantamab mafodotin 3Temozolomide 3Gemcitabine 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2fludarabine phosphate 2enzalutamide 2cemiplimab 2carfilzomib 2abemaciclib 2PF06821497 2Mesna 2Lisaftoclax 2Injections 2Immunotherapy, Adoptive 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Decitabine × 30 days × Clear all
NCT05564650 2026-05-19

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Thomas Jefferson University

Phase 1 Completed
6 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05829226 2026-05-06

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

PureTech

Phase 1 Completed
101 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡